HOWL · Company research
Werewolf Therapeutics, Inc. (HOWL): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
25records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| KRYS Reports Positive Early Data for KB113 in Gorlin Syndrome | Krystal Biotech announced positive pilot study results for KB113, an investigational immunotherapy for basal cell carcinomas in Gorlin syndrome patients. The treatment showed clinical regression in 83.1% of assessed lesions across three patients, including 85.1% regression in non-injected lesions suggesting systemic immune activity. KB113 was well tolerated, and the company has begun FDA discussions on advanced clinical development. | View source ↗ | Zacks Investment Research | Oct 16, 2026 | bullish | 1 | 1 |
| Werewolf Therapeutics files merger registration as HOWL stock faces dilution - ad-hoc-news.de | Werewolf Therapeutics files merger registration as HOWL stock faces dilution ad-hoc-news.de | View source ↗ | ad-hoc-news.de | Oct 16, 2026 | neutral | 0 | 0.6 |
| Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why | Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy) rating based on upward trends in earnings estimates. The company's consensus estimate has increased 17.6% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Werewolf Therapeutics (HOWL) Upgraded to Strong Buy: Here's Why | Werewolf Therapeutics (HOWL) has been upgraded to a Zacks Rank #1 (Strong Buy) rating based on upward trends in earnings estimates. The company's consensus estimate has increased 17.6% over the past three months, positioning it in the top 5% of Zacks-covered stocks. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| TGTX Stock Rises 60% in 6 Months: Here's What You Should Know | TG Therapeutics (TGTX) shares have risen 59.9% over six months, driven by robust sales of its marketed drug Briumvi for relapsing multiple sclerosis. Briumvi sales grew 69% to $437.1 million in the first half of 2026, prompting the company to raise its full-year revenue guidance to approximately $950 million. The company is expanding Briumvi's potential through phase II studies for schizophrenia and myasthenia gravis, and developing a subcutaneous formulation expected to deliver data by end of 2026 or Q1 2027. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases | Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases | Mirum Pharmaceuticals announced that its Phase III EXPAND study met the primary endpoint for Livmarli (maralixibat) in treating cholestatic pruritus in patients with ultra-rare cholestatic liver diseases. Livmarli showed a 1.81-point improvement in itch severity versus 0.83 for placebo and achieved a 69% reduction in serum bile acids. The company plans to submit a supplemental new drug application to the FDA in the first half of 2027. Livmarli sales have grown 50.2% year-over-year in the first half of 2026, reaching $242.5 million. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 0.667 | 1 |
| New Strong Buy Stocks for October 9th | Zacks has added five stocks to its Strong Buy list based on positive earnings estimate revisions over the last 60 days. The stocks include Lumentum Holdings (optical/photonic products), Werewolf Therapeutics (cancer biopharmaceutical), Perion Network (digital advertising), Goldman Sachs BDC (business development), and Griffon Corporation (diversified management). | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| New Strong Buy Stocks for October 9th | Zacks has added five stocks to its Strong Buy list based on positive earnings estimate revisions over the last 60 days. The stocks include Lumentum Holdings (optical/photonic products), Werewolf Therapeutics (cancer biopharmaceutical), Perion Network (digital advertising), Goldman Sachs BDC (business development), and Griffon Corporation (diversified management). | View source ↗ | Zacks Investment Research | Oct 9, 2026 | bullish | 1 | 1 |
| Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History - Benzinga | Werewolf Therapeutics Inc (HOWL) Stock Price, Quote, News & History Benzinga | View source ↗ | Benzinga | Oct 2, 2026 | neutral | 0 | 0.6 |
| German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) - Stock Titan | German investor discloses stake in Werewolf Therapeutics (NASDAQ: HOWL) Stock Titan | View source ↗ | Stock Titan | Sep 21, 2026 | neutral | 0 | 0.6 |
| Wild SPAC deal-hounds howl at moonshots - Breakingviews | Wild SPAC deal-hounds howl at moonshots Breakingviews | View source ↗ | Breakingviews | Sep 11, 2026 | neutral | 0 | 0.6 |
| 1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost - Yahoo Finance | 1 Penny Stock That Could Howl Its Way to the Top After a $150 Million Funding Boost Yahoo Finance | View source ↗ | Yahoo Finance | Aug 26, 2026 | neutral | 0 | 0.6 |
| HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders - The Daily Tribune News | HOWL Stock Alert: Halper Sadeh LLC is Investigating Whether Werewolf Therapeutics, Inc. is Obtaining a Fair Price for its Shareholders The Daily Tribune News | View source ↗ | The Daily Tribune News | Aug 24, 2026 | neutral | 0 | 0.6 |
| Which stocks are moving before the opening bell on Friday? - ChartMill | Which stocks are moving before the opening bell on Friday? ChartMill | View source ↗ | ChartMill | Aug 21, 2026 | neutral | 0 | 0.6 |
| Werewolf Therapeutics stock soars on Ambros merger deal and $150 million PIPE | HOWL Stock News - Quiver Quantitative | Werewolf Therapeutics stock soars on Ambros merger deal and $150 million PIPE | HOWL Stock News Quiver Quantitative | View source ↗ | Quiver Quantitative | Aug 21, 2026 | neutral | 0 | 0.6 |
| Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News - Barchart.com | Little-Known HOWL Stock Skyrockets 100% on Biotech Merger News Barchart.com | View source ↗ | Barchart.com | Aug 21, 2026 | neutral | 0 | 0.6 |
| HOWL Stock Jumps As One-Off Deal Reshapes Outlook - StocksToTrade | HOWL Stock Jumps As One-Off Deal Reshapes Outlook StocksToTrade | View source ↗ | StocksToTrade | Aug 21, 2026 | neutral | 0 | 0.6 |
| Werewolf Therapeutics stock soars 120% on Ambros merger deal - Investing.com | Werewolf Therapeutics stock soars 120% on Ambros merger deal Investing.com | View source ↗ | Investing.com | Aug 21, 2026 | neutral | 0 | 0.6 |
| Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL) - Benzinga | Why Is Werewolf Therapeutics Stock Gaining Friday? - Werewolf Therapeutics (NASDAQ:HOWL) Benzinga | View source ↗ | Benzinga | Aug 21, 2026 | neutral | 0 | 0.6 |
| HOWL Stock Jumps As One-Time Deal Fuels Q2 Profit - Timothy Sykes | HOWL Stock Jumps As One-Time Deal Fuels Q2 Profit Timothy Sykes | View source ↗ | Timothy Sykes | Aug 21, 2026 | neutral | 0 | 0.6 |
| Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE, Holders Locked Up - TradingView | Werewolf Therapeutics to Merge With Ambros in Stock Deal; Raises $150 Million PIPE, Holders Locked Up TradingView | View source ↗ | TradingView | Aug 21, 2026 | neutral | 0 | 0.6 |
| Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing - Yahoo Finance | Werewolf Therapeutics shares surge 120% after Ambros merger and $150 million financing Yahoo Finance | View source ↗ | Yahoo Finance | Aug 21, 2026 | neutral | 0 | 0.6 |
| Werewolf Therapeutics (HOWL) Stock Is Trending Overnight—Here's Why It Jumped 90% After Hours - TradingView | Werewolf Therapeutics (HOWL) Stock Is Trending Overnight—Here's Why It Jumped 90% After Hours TradingView | View source ↗ | TradingView | Aug 20, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.